AEON Biopharma Closes $1.5M Private Placement
Ticker: AEON · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1837607
Sentiment: neutral
Topics: financing, private-placement, stock, warrants
TL;DR
AEON Biopharma just raised $1.5M via a private placement, boosting its cash runway.
AI Summary
AEON Biopharma, Inc. announced on April 12, 2024, the closing of a private placement of its common stock and warrants, raising approximately $1.5 million. The company also entered into a material definitive agreement related to this financing.
Why It Matters
This financing provides AEON Biopharma with additional capital, which is crucial for its ongoing operations and potential development of its pharmaceutical products.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical sector and has raised capital through a private placement, which can indicate ongoing funding needs or early-stage development.
Key Numbers
- $1.5M — Private Placement Proceeds (Capital raised to fund operations and development.)
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- April 12, 2024 (date) — Date of earliest event reported
- $1.5 million (dollar_amount) — Amount raised in private placement
FAQ
What was the total amount raised in the private placement?
The filing indicates that AEON Biopharma, Inc. raised approximately $1.5 million in the private placement.
What securities were issued in the private placement?
The filing mentions the issuance of common stock and warrants in the private placement.
When did the private placement close?
The private placement closed on April 12, 2024.
What is the primary business of AEON Biopharma, Inc.?
AEON Biopharma, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
What other items were reported in this 8-K filing?
In addition to the material definitive agreement and financial obligation related to the private placement, the filing also reported on the departure/election of directors/officers and compensatory arrangements.
Filing Stats: 1,233 words · 5 min read · ~4 pages · Grade level 9.7 · Accepted 2024-04-17 16:06:19
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
- $15.0 m — notes in the principal amount of up to $15.0 million, which are convertible into share
- $0 — mpany's Class A common stock, par value $0.0001, subject to certain conditions and
- $5.0 million — ertible note in the principal amount of $5.0 million. Such convertible note was previously f
- $10.0 million — tible Note") in the principal amount of $10.0 million. The Company will use the net proceeds
Filing Documents
- aeon-20240412x8k.htm (8-K) — 51KB
- aeon-20240412xex4d1.htm (EX-4.1) — 175KB
- aeon-20240412xex4d1002.jpg (GRAPHIC) — 1KB
- 0001837607-24-000033.txt ( ) — 445KB
- aeon-20240412.xsd (EX-101.SCH) — 4KB
- aeon-20240412_def.xml (EX-101.DEF) — 14KB
- aeon-20240412_lab.xml (EX-101.LAB) — 16KB
- aeon-20240412_pre.xml (EX-101.PRE) — 14KB
- aeon-20240412x8k_htm.xml (XML) — 7KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on March 19, 2024, AEON Biopharma, Inc. ("AEON" or the "Company") and AEON Biopharma Sub, Inc., a subsidiary of the Company ("AEON Sub"), entered into a subscription agreement (the "Subscription Agreement") with Daewoong Pharmaceutical Co., LTD. ("Daewoong") relating to the sale and issuance by the Company of senior secured convertible notes in the principal amount of up to $15.0 million, which are convertible into shares of the Company's Class A common stock, par value $0.0001, subject to certain conditions and limitations set forth in each convertible note. The Subscription Agreement was previously filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") by the Company on March 19, 2024. As previously disclosed, on March 24, 2024, AEON issued and sold to Daewoong one senior secured convertible note in the principal amount of $5.0 million. Such convertible note was previously filed as Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC by the Company on March 28, 2024. Subsequent Closing Pursuant to the terms of the Subscription Agreement, on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the "Convertible Note") in the principal amount of $10.0 million. The Company will use the net proceeds from the Convertible Note to support the late-stage clinical development of its lead product candidate ABP-450 and for general working capital purposes. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date. The terms of the Convertible Note are identical to the terms of the Convertible Notes, as described in Item 1.01 of the Company's Current Report on Form 8-K filed with th
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Senior Secured Convertible Note, dated April 12, 2024, by and among AEON Biopharma, Inc., Daewoong Pharmaceutical Co., LTD. and AEON Biopharma Sub, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: April 17, 2024 By: /s/ Marc Forth Marc Forth Chief Executive Officer